secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001628280-26-016652
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen cuts workforce 20%, cites cash management; PALISADE-4 results expected H1 2026
--------------------------------------------------------------------------------

- Reduced workforce by approximately 20% to prioritize fasedienol PALISADE-4 Phase 3 trial.
- Topline results from PALISADE-4 for social anxiety disorder expected first half of 2026.
- Company expects cash runway to extend into 2027 after the workforce reduction.
- Affected employees may receive cash severance and healthcare coverage; costs expected immaterial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/0001628280-26-016652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/vtgn-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer